Drug intelligence / Profile preview

HL101

Development stage: Preclinical
Lead developer: Shenzhen Zero-One Life Technology
Modality: Small Molecules
Administration: Topical

Overview

HL101 is a topical small molecule new molecular entity (NME) being developed by Shenzhen 01 Life Technology (01Life) for the treatment of hair loss (alopecia). The compound is derived from metabolites of human skin commensal bacteria, representing a microbiome-based approach to dermatological therapy. HL101 is currently in the IND-enabling stage of development, aimed at providing a novel therapeutic option for patients suffering from various forms of alopecia.

Beyond the preview

Go deeper on HL101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL101.

Explore the full profile